Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7855614 | 1.00 | HSD17B10 (0.49) | HSD17B10HPGDCTSKSMN1; SMN2NPC1 | |
| SCHEMBL5171011 | 1.00 | HSD17B10 (0.49) | HSD17B10HPGDCTSKSMN1; SMN2NPC1 | |
| SCHEMBL9555116 | 0.95 | HPGD (0.48) | HSD17B10HPGDCTSKSMN1; SMN2NPC1 | |
| SCHEMBL7380781 | 0.95 | HPGD (0.48) | HSD17B10HPGDCTSKSMN1; SMN2NPC1 | |
| SCHEMBL9554546 | 0.90 | CTSK (0.42) | HSD17B10HPGDCTSKSMN1; SMN2ALDH1A1 | |
| SCHEMBL10512917 | 0.87 | HSD17B10 (0.47) | HSD17B10HPGDCTSKSMN1; SMN2NPC1 | |
| SCHEMBL889059 | 0.85 | HSD17B10 (0.55) | HSD17B10HPGDCTSKSMN1; SMN2NPC1 | |
| SCHEMBL231219 | 0.85 | HSD17B10 (0.55) | HSD17B10HPGDCTSKSMN1; SMN2NPC1 | |
| SCHEMBL240005 | 0.85 | DPP4 (0.56) | HSD17B10CTSK | |
| SCHEMBL1357066 | 0.85 | DPP4 (0.56) | HSD17B10CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536714-A2 | A NOVEL 5-MEMBERED HETEROCYCLE DERIVATIVES AND MANUFACTURING PROCESS THEREOF | Il-Dong Pharm. Co., Ltd. (KR) | 2012-12-26 | — | — | EP | claimed |
| US-20120309750-A1 | 5-MEMBERED HETEROCYCLE DERIVATIVES AND MANUFACTURING PROCESS THEREOF | ILDONG PHARM CO., LTD. (KR) | 2012-12-06 | — | — | US | claimed |
| WO-2011102660-A2 | A NOVEL 5-MEMBERED HETEROCYCLE DERIVATIVES AND MANUFACTURING PROCESS THEREOF | ILDONG PHARM CO., LTD. (KR) | 2011-08-25 | — | — | WO | claimed |
| EP-1021424-B1 | THIADIAZOLE AMIDE MMP INHIBITORS | UPJOHN CO (US) | 2003-02-26 | — | — | EP | claimed |
| EP-0973517-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2002-07-24 | — | — | EP | claimed |
| US-6288105-B1 | COMPOUNDS SUCH AS (S)-2-(4-((2-AMINO-3-HYDROXY-1-OXOPROPYL)AMINO)PHENYL)-6-HYDRO XY-3-(3-METHOXY-4-(1-PYRROLIDINYLMETHYL)BENZYL)BENZO(B)THIOPHE NE | ELI LILLY AND COMPANY | 2001-09-11 | — | — | US | claimed |
| EP-1021424-A1 | THIADIAZOLE AMIDE MMP INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-26 | — | — | EP | claimed |
| EP-0973517-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-01-26 | — | — | EP | claimed |
| WO-1998048794-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | claimed |
| WO-1997048688-A1 | THIADIAZOLE AMIDE MMP INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-24 | — | — | WO | claimed |
| US-4760061-A | Antioestrogenic agent | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-07-26 | — | — | US | claimed |
| CN-106188175-B | Treatment of klebsiella pneumoniae infections with antibacterial aminoglycoside compounds | 轩竹(北京)医药科技有限公司 | 2020-08-11 | — | — | CN | disclosed |
| CN-105218632-A | As peptide or plan peptide, the Preparation Method And The Use of transglutaminase inhibitor | ZEDIRA GMBH | 2016-01-06 | — | — | CN | disclosed |
| EP-2536714-A2 | A NOVEL 5-MEMBERED HETEROCYCLE DERIVATIVES AND MANUFACTURING PROCESS THEREOF | Il-Dong Pharm. Co., Ltd. (KR) | 2012-12-26 | — | — | EP | disclosed |
| US-20120309750-A1 | 5-MEMBERED HETEROCYCLE DERIVATIVES AND MANUFACTURING PROCESS THEREOF | ILDONG PHARM CO., LTD. (KR) | 2012-12-06 | — | — | US | disclosed |
| EP-0145768-A1 | CYCLIC PENTAPEPTIDES DISPLAYING SOMATOSTATIN ANTAGONISM AND METHOD OF TREATMENT OF MAMMALS THEREWITH | COY, David Howard (US) | 1985-06-26 | — | — | EP | disclosed |
| US-4505897-A | INCREASING RELEASE OF GROWTH HORMONE, INSULIN, AND GLUCAGON | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 1985-03-19 | — | — | US | disclosed |
| WO-1984004916-A1 | CYCLIC PENTAPEPTIDES DISPLAYING SOMATOSTATIN ANTAGONISM AND METHOD OF TREATMENT OF MAMMALS THEREWITH | COY DAVID HOWARD (US) | 1984-12-20 | — | — | WO | disclosed |
| EP-0127899-A1 | Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith | The Administrators of The Tulane University Educational Fund (US) | 1984-12-12 | — | — | EP | disclosed |
| EP-0034260-B1 | PEPTIDES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS OR DIAGNOSTIC AGENTS CONTAINING THEM | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1983-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309750-A1 | 5-MEMBERED HETEROCYCLE DERIVATIVES AND MANUFACTURING PROCESS THEREOF | CYP3A5, UGT2B7, UGT1A7 | HSD17B10 303/4885HPGD 90/4885CTSK 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.